Multinational pharma giant AstraZeneca said Tuesday that it has agreed to acquire worldwide rights to develop and commercialize a lung cancer drug for as much as $1.5 billion from Chinese pharma company Dizal Pharmaceutical Co. Ltd.
Multinational pharma giant AstraZeneca said Tuesday that it has agreed to acquire worldwide rights to develop and commercialize a lung cancer drug for as much as $1.5 billion from Chinese pharma company Dizal Pharmaceutical Co. Ltd.
Shell has said it will sell its Indian renewables platform to Aditya Birla for $1.8 billion, less than four years after buying the business, as the oil giant reduces exposure to certain parts of its power generation assets.
Flooring company Victoria PLC said Tuesday that it has completed the €34.4 million ($40 million) sale-and-leaseback of its Belgian distribution center as it continues to shift much of its Balta Rugs manufacturing to Turkey.
A director who covertly sabotaged his board's strategy to sell a business breached his statutory duty to act in good faith, Britain's top court ruled Tuesday, holding that his belief that he was acting in the company's long-term interests did not excuse his conduct.
The Treasury's champion of wholesale digital markets, Chris Woolard, has set out for Chancellor Rachel Reeves a 12-month plan to get companies, regulators and the government to develop online assets in wholesale financial markets.
The Financial Conduct Authority said Tuesday that its board has appointed former Macfarlanes LLP lawyer Dan Lavender to its committee that ensures contested enforcement decisions are made fairly.
Poolbeg Pharma PLC said Tuesday it has conditionally raised £3.5 million ($4.7 million) through a share sale to fund two clinical trials through to completion and boost its position in talks with potential partners.
Ropes & Gray LLP is set to lose a finance lawyer to rival Kirkland & Ellis LLP in Paris, a little more than a year after Ropes & Gray opened its office in the French capital.
Though proposed updates would result in greater overlap between European Commission merger control efforts and foreign investment screening, dealmakers must understand how different objectives still drive these regimes and how this recalibrated regulatory environment will affect their transactions, say attorneys at Mayer Brown.
